Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salvage Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Combined With Post-transplant Relapse Prevention Strategies for Relapsed/Refractory Acute Myeloid Leukemia (AML): A Prospective Observational Study

NCT07572695 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07572695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07572695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Salvage Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Combined With Post-transplant Relapse Prevention Strategies for Relapsed/Refractory Acute Myeloid Leukemia (AML): A Prospective Observational Study
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Observational
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, relapsed/refractory, relapsed/refractory acute myeloid leukemia